Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278028 · ClinicalTrials.gov registry record · Phase 2
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
A Phase 2 study of Common Wart, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 16
- Study locations
NCT03278028 is a Phase 2 study of Common Wart that has completed, run by Aclaris Therapeutics. The registered enrollment target is 159 participants. The trial reports 16 study locations across 12 states.
The verdict
NCT03278028, a Phase 2 study of Common Wart, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
Conditions Studied
Interventions
- DRUG A-101 Topical Solution
- DRUG A-101 Vehicle Solution
Study Locations (16)
California
- Aclaris Investigational Site - Encinitas
- Aclaris Investigational Site - Los Angeles
Tennessee
- Aclaris Investigational Site - Knoxville
- Aclaris Investigational Site - Nashville
Texas
- Aclaris Investigational Site - College Station
- Aclaris Investigational Site - Houston
Virginia
- Aclaris Investigational Site - Lynchburg
- Aclaris Investigational Site - Norfolk
Arizona
- Aclaris Investigational Site - Glendale
Arkansas
- Aclaris Investigational Site - Fort Smith
Colorado
- Aclaris Investigational Site - Denver
Nebraska
- Aclaris Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03278028
The ClinicalTrials.gov registry entry for NCT03278028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Common Wart appearing as the primary indexed condition, and to 2 interventions - of which A-101 Topical Solution is the first listed.
NCT03278028 reports 16 study locations spanning 12 distinct geographic areas - top geographies include California, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT03278028 about?
NCT03278028 is a clinical study titled "A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts". The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
What is the current status of trial NCT03278028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2017-07-13. Estimated completion is 2018-03-01.
What conditions does trial NCT03278028 study?
This clinical trial studies the following conditions: Common Wart.
What interventions are being tested in trial NCT03278028?
The interventions under investigation include: A-101 Topical Solution (DRUG), A-101 Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT03278028?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03278028 being conducted?
This trial has 16 study locations across Arizona, Arkansas, California, Colorado, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Wart
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.